美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

美国抗疫概念

1,407.30

-8.2197-0.58%

涨家数：3

跌家数：15

平家数：2

市盈率：- -

高：1,416.47

开：1,412.17

低：1,403.91

收：1,415.52

数据加载中...

数据：六月份超过27亿美元的代币将解锁

强生：首次公布 FIC 双抗前列腺癌数据，BCMA/GPRC5D/CD3 三抗人体数据首次亮相...

Insight数据库

阿斯利康乳腺癌药物可延缓病情超六个月

环球市场播报

吉利德的 CAR-T 细胞疗法有望治疗致命的脑癌

阿斯利康公布 PD-1×TIGIT 双抗、CD19×CD3 双抗临床数据

Insight数据库

新华财经早报：6月1日

中国金融信息网

辉瑞占先发优势，Alnylam、BridgeBio紧跟，ATTR-CM三强鏖战

医药经济报

更正-辉瑞-阿维那乳腺癌药物在延缓病情恶化方面优于阿斯利康药物

吉利德公司的 Trodelvy 与 Keytruda 一起在试验中将乳腺癌风险降低了 35

亚太电信组织信息通信技术部长会议在日本东京召开

Moderna(MRNA.O)预计将在2025-2026年呼吸道病毒季节为符合条件的美国人群提供MNEXSPIKE疫苗。

Moderna(MRNA.O)获得美国食品药品监督管理局（FDA）批准其新冠病毒疫苗MNEXSPIKE。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK4568/news?page=9"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"美国抗疫概念","latestPrice":1407.301,"timestamp":1749844799999,"preClose":1415.5208,"halted":0,"volume":120542094,"delay":0,"changeRate":-0.005807,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-8.219727,"latestTime":"06-13 16:00:00 EDT","open":1412.1731,"high":1416.4696,"low":1403.9053,"amount":4255045914.078211,"amplitude":0.008876,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.748473,"peRate":22.310833,"turnoverRate":0.00777,"increases":3,"decrements":15,"flats":2,"marketCap":1159992667614.25,"floatMarketCap":1139677427989},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1416.4696,"amplitude":0.008876,"preClose":1415.5208,"low":1403.9053,"pbRate":"3.748473","latestPrice":1407.301,"volume":120542094,"delay":0,"open":1412.1731,"prevYearClose":1274.8187,"prevWeekClose":1387.2587,"prevMonthClose":1383.2164,"prevQuarterClose":1427.887,"fiveDayClose":1387.2587,"twentyDayClose":1322.3966,"sixtyDayClose":1423.3892,"secType":"PLATE","market":"US","turnoverRate":0.00777,"peRate":22.310833,"marketCap":1159992667614.25,"floatMarketCap":1139677427989,"timestamp":1749844799999,"nameCN":"美国抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":3,"down":15,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540750223","title":"数据：六月份超过27亿美元的代币将解锁","url":"https://stock-news.laohu8.com/highlight/detail?id=2540750223","media":"金色财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540750223?lang=zh_cn&edition=fundamental","pubTime":"2025-06-02 14:36","pubTimestamp":1748846207,"startTime":"0","endTime":"0","summary":null,"market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://x.com/Cointelegraph/status/1929425273386123325","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinse_live","symbols":["APT.USD.CC","BK4086","BK4228","BK4568","BK4215","APT","APT.USD.HKCC","SUI"],"gpt_icon":0},{"id":"2540752022","title":"强生：首次公布 FIC 双抗前列腺癌数据，BCMA/GPRC5D/CD3 三抗人体数据首次亮相...","url":"https://stock-news.laohu8.com/highlight/detail?id=2540752022","media":"Insight数据库","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540752022?lang=zh_cn&edition=fundamental","pubTime":"2025-06-02 13:00","pubTimestamp":1748840400,"startTime":"0","endTime":"0","summary":"本次公布结果的是一项该药治疗转移性去势抵抗性前列腺癌的 I 期研究。主要目的是确定安全性和 RP2D。次要目的包括初步评估抗肿瘤活性。在安全性方面，无 JNJ-78278343 相关的死亡病例。并且这些结果对 mCRPC 具有临床意义，III 期临床试验正在计划中。本次是该药首次披露 I 期人体研究数据。5 名患者出现剂量限制性毒性，4 名因AE死亡。截至 2024 年 5 月 1 日，中位随访时间为 33.6 个月。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602130208a49633c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602130208a49633c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","IE00B3T34201.USD","LU0882574055.USD","LU2129689605.HKD","LU1585245621.USD","IE0002270589.USD","SG9999002232.USD","IE00BN8TJ469.HKD","LU1023059063.AUD","LU1061106388.HKD","LU2347655156.SGD","IE0034235303.USD","JNJ","LU1430594728.SGD","LU0795875169.SGD","LU0889566641.SGD","IE00BVYPNW00.USD","LU1066051225.USD","LU0345770993.USD","LU1244550577.SGD","IE00BGHQF631.EUR","BK4592","IE00B2B36J28.USD","LU2468319806.SGD","LU2430703178.SGD","IE00B19Z3581.USD","LU1674673691.USD","LU2112291526.USD","LU1261432733.SGD","LU0289739699.SGD","LU1506573853.SGD","LU1066051498.USD","IE00BJJMRZ35.SGD","LU1914381329.SGD","IE00B42XCP33.USD","LU2602419157.SGD","LU0234570918.USD","LU1196500208.SGD","LU0795875086.SGD","LU1732799900.SGD","IE00B1BXHZ80.USD","LU2133065610.SGD","IE00BFTCPJ56.SGD","LU0234572021.USD","LU2129689514.USD","LU2430703251.USD","LU0203347892.USD","LU1929549753.HKD","LU1032955483.USD","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2540731098","title":"阿斯利康乳腺癌药物可延缓病情超六个月","url":"https://stock-news.laohu8.com/highlight/detail?id=2540731098","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540731098?lang=zh_cn&edition=fundamental","pubTime":"2025-06-01 20:14","pubTimestamp":1748780072,"startTime":"0","endTime":"0","summary":"根据一项可能吸引投资者关注的新研究数据，阿斯利康公司的实验性乳腺癌药物将疾病进展延迟了六个多月。　　Camizestrant 与其他抗癌药物联合使用时，帮助特定类型乳腺癌患者的无进展生存期中位数达到 16 个月，相比之下，接受当前标准治疗的患者为 9.2 个月。　　考虑到 Camizestrant 的其他潜在用途，阿斯利康认为该药物的年销售额可能超过 50 亿美元。　　阿斯利康正在与美国食品和药物管理局就相关数据进行讨论。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-06-01/doc-ineyqshv8582094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["LU0320765992.SGD","BK4568","LU2456880835.USD","LU2236285917.USD","LU2462157665.USD","LU1829250122.USD","LU0109394709.USD","LU2417539215.USD","BK4585","BK4007","AZN","BK4588","LU0889565916.HKD"],"gpt_icon":0},{"id":"2540731235","title":"吉利德的 CAR-T 细胞疗法有望治疗致命的脑癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2540731235","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540731235?lang=zh_cn&edition=fundamental","pubTime":"2025-06-01 20:00","pubTimestamp":1748779203,"startTime":"0","endTime":"0","summary":"CAR-T疗法已被用于治疗血癌，包括白血病、淋巴瘤和多发性骨髓瘤，这些疗法通常只针对肿瘤的一个靶点。通常情况下，晚期胶质母细胞瘤患者在接受手术、放疗和化疗等初步治疗后，其癌症复发的生存期为6 到 10 个 月。目前的研究包括 18 名接受标准治疗后肿瘤复发的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250601:nL3S3S402T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4550","LU1674673428.USD","LU2468319806.SGD","IE00B19Z3B42.SGD","LU0320765992.SGD","LU0289739699.SGD","BK4566","IE00BSNM7G36.USD","GILD","LU2087621335.USD","LU1778281490.HKD","IE00B19Z3581.USD","LU1430594728.SGD","BK4139","LU2089984988.USD","IE00B7SZLL34.SGD","LU1674673691.USD","LU1571399168.USD","LU0889565916.HKD","LU0234570918.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1585245621.USD","BK4578","LU0823416689.USD","BK4583","LU0109394709.USD","LU1066053197.SGD","IE00B3T34201.USD","BK4585","LU0058720904.USD","LU1839511570.USD","BK4532","LU1066051498.USD","IE0002270589.USD","BK4568"],"gpt_icon":0},{"id":"2540373585","title":"阿斯利康公布 PD-1×TIGIT 双抗、CD19×CD3 双抗临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2540373585","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540373585?lang=zh_cn&edition=fundamental","pubTime":"2025-06-01 13:30","pubTimestamp":1748755800,"startTime":"0","endTime":"0","summary":"本文将分享 Rilvegostomig、AZD0486的三项研究数据。Insight 数据显示，阿斯利康尚无双抗药物获批上市。截至 2024 年 11 月 4 日，所有患者的中位随访时间为 6.9 个月，36.7% 的患者仍在接受 Rilve 治疗。截至 2024 年 10 月 24 日，40 例患者接受了 Dato-DXd + Rilvegostomig 治疗；29 例患者为非鳞状组织学患者。23% 的患者出现≥G3 级中性粒细胞减少症，14% 的患者出现≥G3 级贫血。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250601133331a494fa99&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250601133331a494fa99&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1169590202.USD","BK4568","LU0320765992.SGD","LU1829250122.USD","LU2236285917.USD","LU2462157665.USD","AZN","LU2456880835.USD","PD","BK4588","BK4585","BK4007","LU0109394709.USD","LU1169589451.USD","BK4023","LU0889565916.HKD","LU2417539215.USD"],"gpt_icon":0},{"id":"2540804607","title":"新华财经早报：6月1日","url":"https://stock-news.laohu8.com/highlight/detail?id=2540804607","media":"中国金融信息网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540804607?lang=zh_cn&edition=fundamental","pubTime":"2025-06-01 08:55","pubTimestamp":1748739300,"startTime":"0","endTime":"0","summary":"据网络平台数据显示，截至5月31日21时，2025年端午档首日票房1.47亿元。香港特别行政区政府于5月30日在宪报刊登《稳定币条例》，这意味着《稳定币条例》正式成为法例。此前，香港立法会已经在5月21日正式通过该条例草案，用以在香港设立“法币稳定币” 发行人的发牌制度。5月30日，中国一重集团有限公司、中国核工业集团有限公司官宣换帅，官网“领导团队”“领导班子”栏目均已做出调整。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-06-01/doc-ineypqvi9106174.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4086","APT","BK4568"],"gpt_icon":0},{"id":"2540803707","title":"辉瑞占先发优势，Alnylam、BridgeBio紧跟，ATTR-CM三强鏖战","url":"https://stock-news.laohu8.com/highlight/detail?id=2540803707","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540803707?lang=zh_cn&edition=fundamental","pubTime":"2025-06-01 08:03","pubTimestamp":1748736216,"startTime":"0","endTime":"0","summary":"2024年11月，BridgeBio公司开发的TTR稳定剂Attruby也获得FDA批准用于治疗ATTR-CM成年患者，目前销售势头良好。Alnylam公司首席商务官Tolga Tanguler认为，相较tafimidis或BridgeBio公司的Attruby需每日口服给药，Amvuttra全年仅需进行4次皮下注射给药，有望提高患者依从性。但是，BridgeBio公司认为，其药物在稳定TTR方面的效果优于辉瑞的产品。辉瑞优势地位暂时无忧虽然Alnylam公司和BridgeBio公司都在挑战辉瑞，但从销售额来看，辉瑞目前仍居有利地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250601083413a494b83d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250601083413a494b83d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0225284248.USD","LU0985481810.HKD","LU0289739699.SGD","IE000M9KFDE8.USD","BK4533","BK4581","LU0058720904.USD","BK4588","SG9999002232.USD","CM","SG9999013999.USD","LU1066051498.USD","IE0002270589.USD","BK4550","IE00B19Z3581.USD","LU0122379950.USD","BK4534","BK4592","IE00BBT3K403.USD","IE00BLSP4452.SGD","LU1057294990.SGD","SG9999001176.SGD","SG9999001176.USD","BK4599","LU1883839398.USD","BK4568","LU0306807586.USD","LU0868494617.USD","BK4007","LU0456855351.SGD","LU0306806265.USD","LU0321505439.SGD","BK4207","LU0234572021.USD","LU1023059063.AUD","SG9999011175.SGD","BK4585","SG9999002224.SGD","LU0170899867.USD","LU0321505868.SGD","LU1894683348.USD","LU1894683264.USD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","PFE","SG9999003800.SGD","SGXZ57979304.SGD","LU0225771236.USD","LU1066053197.SGD"],"gpt_icon":1},{"id":"2539786188","title":"更正-辉瑞-阿维那乳腺癌药物在延缓病情恶化方面优于阿斯利康药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2539786188","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539786188?lang=zh_cn&edition=fundamental","pubTime":"2025-05-31 20:00","pubTimestamp":1748692832,"startTime":"0","endTime":"0","summary":"路透社5月31日 - 辉瑞PFE.N和ArvinasARVN.O公司周六公布的试验结果显示，与阿斯利康AZN.L公司的Faslodex相比，辉瑞PFE.N和ArvinasARVN.O公司的一种实验性疗法可将乳腺癌患者的病情恶化时间推迟三个多月。该试验发现，实验性药物 vepdegestrant 可使 ESR1 基因突变患者在病情没有恶化的情况下生存 5 个月，而 Faslodex 仅能生存约 2 个月。周六公布的更详细数据显示，vepdegestrant能使更大样本患者的生存期延长3.8个月，而Faslodex的生存期仅为3.6个月。据美国癌症协会称，乳腺癌约占美国每年新发女性癌症的三分之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nL3T3S302N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK5011","LU0122379950.USD","BK4533","LU1894683348.USD","LU2089284900.SGD","LU2279689827.SGD","IE00B4R5TH58.HKD","LU0077335932.USD","LU1989771016.USD","LU2023251221.USD","LU1061106388.HKD","IE00BLSP4452.SGD","LU1084165304.USD","SG9999002224.SGD","LU1989772840.SGD","IE000M9KFDE8.USD","AZN.UK","LU0889565080.SGD","LU1481600234.SGD","BK4007","PFE","IE00BLSP4239.USD","LU0882574055.USD","LU0310800379.SGD","IE0002270589.USD","IE0034235188.USD","LU0957799991.USD","LU1051770623.HKD","LU0868494617.USD","LU1989772923.USD","LU0047473722.EUR","LU1301847155.USD","LU0949170426.SGD","LU0029864427.USD","ARVN","LU1983299246.USD","LU0545039389.USD","BK4581","LU0234572021.USD","LU0211326755.USD","03165","LU0557290698.USD","LU0969580561.USD","BK4568","LU1323610961.USD","BK4588","LU0203347892.USD","SG9999001176.SGD","LU1023059063.AUD","LU0963555726.SGD"],"gpt_icon":1},{"id":"2539861837","title":"吉利德公司的 Trodelvy 与 Keytruda 一起在试验中将乳腺癌风险降低了 35","url":"https://stock-news.laohu8.com/highlight/detail?id=2539861837","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539861837?lang=zh_cn&edition=fundamental","pubTime":"2025-05-31 20:00","pubTimestamp":1748692810,"startTime":"0","endTime":"0","summary":"路透社5月31日 - 据周六公布的一项大型试验结果显示，吉利德科学公司的GILD.OTrodelvy与默克公司的MRK.N大片免疫疗法Keytruda联合使用作为初始治疗时，一种侵袭性乳腺癌恶化的风险降低了35%。该医疗小组表示，约 40% 的三阴性乳腺癌也是 PD-L1 阳性，因此也是 Keytruda 的候选对象。吉利德公司正在进行其他几项 Trodelvy 研究，包括将该药作为不表达 PD-L1 的三阴性乳腺癌患者的初始治疗药物的试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nL3S3S302J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014575.USD","LU1989771016.USD","SG9999002224.SGD","IE00BLSP4452.SGD","LU1989772840.SGD","BK4139","BK4578","IE00BN8TJ469.HKD","IE00B7SZLL34.SGD","LU0211331839.USD","BK4007","SG9999015341.SGD","LU2089984988.USD","LU1291159041.SGD","LU1035773651.USD","LU0058720904.USD","LU1066051811.HKD","IE0002270589.USD","LU1699723380.USD","LU0106261372.USD","LU1974910355.USD","LU0208291251.USD","IE00BKVL7J92.USD","LU1989772923.USD","BK4532","BK4585","IE00B19Z3B42.SGD","IE00BZ1G4Q59.USD","SG9999014567.USD","LU2023250504.SGD","LU1430594728.SGD","SG9999014542.SGD","LU1983299246.USD","LU0266013472.USD","LU1571399168.USD","LU0823416689.USD","SG9999001440.SGD","GILD","LU1934455277.USD","LU0265550946.USD","BK4568","BK4588","LU0265550359.USD","LU1585245621.USD","LU0070302665.USD","LU2324357040.USD","LU1093756168.USD","SG9999001176.SGD","LU0965508806.USD","MRK"],"gpt_icon":0},{"id":"2539207181","title":"亚太电信组织信息通信技术部长会议在日本东京召开","url":"https://stock-news.laohu8.com/highlight/detail?id=2539207181","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539207181?lang=zh_cn&edition=fundamental","pubTime":"2025-05-31 13:07","pubTimestamp":1748668058,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["APT","APT.USD.HKCC","161022","BK4086","APT.USD.CC","BK4568"],"gpt_icon":0},{"id":"2539027032","title":"Moderna(MRNA.O)预计将在2025-2026年呼吸道病毒季节为符合条件的美国人群提供MNEXSPIKE疫苗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2539027032","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539027032?lang=zh_cn&edition=fundamental","pubTime":"2025-05-31 12:21","pubTimestamp":1748665310,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ab08e83891bd4f6befe17195e6627dcc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["MRNA","BK4533","BK4548","BK4551","BK4568","BK4139","BK4534","BK4588","BK4532","BK4585","159646","BK4501"],"gpt_icon":0},{"id":"2539202708","title":"Moderna(MRNA.O)获得美国食品药品监督管理局（FDA）批准其新冠病毒疫苗MNEXSPIKE。","url":"https://stock-news.laohu8.com/highlight/detail?id=2539202708","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539202708?lang=zh_cn&edition=fundamental","pubTime":"2025-05-31 12:21","pubTimestamp":1748665294,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ab08e83891bd4f6befe17195e6627dcc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4534","BK4551","BK4501","BK4533","BK4548","159646","MRNA","BK4588","BK4568","BK4585","BK4532","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":9,"totalSize":172,"code":"91000000","status":"200"}]}}